Threshold Pharma Offers Preclinical Data Suggesting TH-4000 Could Overcome Resistance to Conventional EGFR Tyrosin Kinase Inhibitors
April 22, 2015 at 08:03 AM EDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced preclinical data on TH-4000, its proprietary, molecularly-targeted, ...